Related Experiment Videos
Impact of cyclosporine on cadaveric renal transplantation: a summary statement
Insights
Cyclosporine (CsA) is the preferred immunosuppressant for kidney transplants, improving graft survival by 10%. It benefits high-risk patients and reduces rejection episodes, aiding patient rehabilitation.
Area of Science:
- Nephrology
- Immunosuppression
- Transplantation immunology
Background:
- Cyclosporine (CsA) has been available in the US for over a year.
- Extensive clinical experience with CsA has been gathered over four years.
Purpose of the Study:
- To evaluate the efficacy of CsA as an immunosuppressive agent in cadaveric renal allografts.
- To assess the benefits of CsA in high-risk patient populations.
- To review the ongoing debate regarding transfusion and HLA matching with CsA therapy.
Main Methods:
- Analysis of US national experience with CsA in renal transplantation.
- Comparison of graft survival rates between CsA-treated and other immunosuppressed patients.
- Review of clinical outcomes, including rejection episodes, steroid dosage, and patient rehabilitation.
Main Results:
- CsA offers a 10% advantage in graft survival for cadaveric renal allografts, except in HLA-DR matched recipients.
- CsA is particularly beneficial for high-risk patients (e.g., >50 years old, diabetics).
- CsA reduces rejection frequency and allows for lower steroid doses, improving patient rehabilitation.
Conclusions:
- CsA is the immunosuppressive agent of choice for most renal allografts.
- Further research is needed to clarify the roles of transfusion and HLA matching in CsA therapy.
- Long-term monitoring is essential to fully understand the impact of CsA on transplantation outcomes.
Abstract:
CsA has now been used in this country for about four years and has been widely available for a little more than one year. Both the experience of those centers that have been using it longest, and total US national experience, suggest that CsA is now, with the sole exception of recipients matched for both HLA-DR antigens, the immunosuppressive of choice for all cadaveric renal allografts, conferring approximately a 10% advantage in graft survival. The advantages of CsA seem particularly apparent in the management of high-risk patients such as those over 50 years old and those with diabetes. CsA appears to reduce the frequency of rejection episodes and to permit reduction of steroid dosage. These factors, together with the improved graft survival rate, may contribute to a substantially higher rate of patient rehabilitation. The role of transfusion and HLA matching in association with CsA remains somewhat controversial. While large multicenter studies show the continued importance of both transfusion and optimal HLA matching, it has been argued that avoidance of pretransplant transfusions has avoided presentation of potential recipients, and that simplification of matching requirements has saved money and has permitted speedier transplantation of patients, favoring improved rehabilitation. Careful monitoring of the experience with this major new immunosuppressive agent over the next several years may answer these remaining questions.